- Home
- CSTL vs TWFG Comparison
CSTL vs TWFG Comparison
Compare CSTL & TWFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- TWFG
- Stock Information
- Founded
- CSTL 2007
- TWFG 2001
- Country
- CSTL United States
- TWFG United States
- Employees
- CSTL N/A
- TWFG N/A
- Industry
- CSTL Medical Specialities
- TWFG
- Sector
- CSTL Health Care
- TWFG
- Exchange
- CSTL Nasdaq
- TWFG NYSE
- Market Cap
- CSTL 456.2M
- TWFG 530.3M
- IPO Year
- CSTL 2019
- TWFG 2024
- Fundamental
- Price
- CSTL $19.46
- TWFG $35.41
- Analyst Decision
- CSTL Strong Buy
- TWFG Buy
- Analyst Count
- CSTL 6
- TWFG 8
- Target Price
- CSTL $37.67
- TWFG $33.71
- AVG Volume (30 Days)
- CSTL 462.3K
- TWFG 120.2K
- Earning Date
- CSTL 08-04-2025
- TWFG 08-26-2025
- Dividend Yield
- CSTL N/A
- TWFG N/A
- EPS Growth
- CSTL N/A
- TWFG N/A
- EPS
- CSTL N/A
- TWFG N/A
- Revenue
- CSTL $347,083,000.00
- TWFG $211,440,000.00
- Revenue This Year
- CSTL N/A
- TWFG $23.90
- Revenue Next Year
- CSTL $1.36
- TWFG $22.60
- P/E Ratio
- CSTL N/A
- TWFG N/A
- Revenue Growth
- CSTL 38.43
- TWFG 18.57
- 52 Week Low
- CSTL $15.45
- TWFG $21.31
- 52 Week High
- CSTL $35.84
- TWFG $36.85
- Technical
- Relative Strength Index (RSI)
- CSTL 55.41
- TWFG N/A
- Support Level
- CSTL $18.18
- TWFG N/A
- Resistance Level
- CSTL $20.63
- TWFG N/A
- Average True Range (ATR)
- CSTL 0.77
- TWFG 0.00
- MACD
- CSTL 0.07
- TWFG 0.00
- Stochastic Oscillator
- CSTL 57.36
- TWFG 0.00
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About TWFG TWFG INC
TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.